Hepatotoxicity induced by alendronate therapy.
Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy was discontinued, the patient's hepatic enzyme levels slowly returned to normal. Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect.
Yanik
B
B
Department of Physical Medicine and Rehabilitation, Fatih University School of Medicine, Ankara, Turkey. burcucorek@hotmail.com
Turkay
C
C
Atalar
H
H
D019386:Alendronate / Q000009:adverse effects* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy
D050071:Bone Density Conservation Agents; D019386:Alendronate